Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

Completed

• Conditions: Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
• Interventions: Drug: Rabeprazole Sodium

• Registration Number: NCT01264822
• Lead Sponsor: Eisai Co., Ltd.

Brief Summary

To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-12-20
• Study First Submitted QC: 2010-12-21
• Study First Posted: 2010-12-22
• Study Start: 2011-01-13
• Primary Completion: 2016-02-29
• Study Completion: 2016-11-17
• Status Verified: 2017-01
• Last Update Submitted: 2017-02-23
• Last Update Posted: 2017-02-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Treatment Arm 1 Rabeprazole Sodium	Rabeprazole Sodium	-

Primary Outcome Measures

Name	Time	Method
Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori	Every 3 months within the 1st year and every 6 months
Transition rate to secondary therapy for eradication of Helicobacter pylori	Every 6 months within the 1st year and every 12 months as needed